CD20阳性血管免疫母细胞性T细胞淋巴瘤1例及文献复习

CD20-positive angioimmunoblastic T cell lymphoma:An analysis of one case and literatures review

目的:探讨CD20阳性血管免疫母细胞性T细胞淋巴瘤(angioimmunoblastic T cell lymphoma,AITL)的临床特征及预后。方法:回顾分析我院1例CD20阳性AITL患者的临床病理特征、治疗转归并复习相关文献。结果:患者男性,69岁,以水肿及腹腔积液为首发表现,CT提示全身淋巴结肿大。免疫表型:CD20阳性、CD3(+)、CD5(+)、Ki-67(+,85%),其它B细胞标记阴性,EBER原位杂交阳性,TCR基因重排及IGH单克隆性重排阳性,多种治疗方案均无效。结论:CD20阳性AITL患者的临床病理特征易与B细胞淋巴瘤混淆,病理形态学、免疫组织化学及TCR基因重排检测等可减少误诊。利妥昔单抗及其他靶向药物的应用可能提高治愈率,改善患者预后。

Objective:To investigate the clinical characteristics and prognosis of CD20-positive angioimmunoblastic T cell lymphoma(AITL).Methods:The clinicopathological features,treatment outcome of 1 case of CD20-positive AITL in our hospital were retrospectively analyzed.Results:A 69-year-old male showed edema and peritoneal effusion,and CT indicated systemic lymph nodes.Immunophenotypes showed CD20 positive,CD3(+),CD5(+),Ki-67(+,85%),other B cell markers negative,EBER in situ hybridization positive,TCR gene rearrangement and IGH monoclonal rearrangement positive,a variety of treatment options are not effective.Conclusion:The clinicopathological features of CD20-positive AITL patients are easily confused with B-cell lymphoma.Pathomorphology,immunohistochemistry and TCR gene rearrangement can reduce misdiagnosis.Rituximab and other targeted drugs may improve the cure rate and prognosis of patients.